<SEC-DOCUMENT>0001104659-21-105569.txt : 20210816
<SEC-HEADER>0001104659-21-105569.hdr.sgml : 20210816
<ACCEPTANCE-DATETIME>20210816071852
ACCESSION NUMBER:		0001104659-21-105569
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210816
FILED AS OF DATE:		20210816
DATE AS OF CHANGE:		20210816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		211174487

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2125173d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of August, 2021</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
<TD STYLE="width: 2%"></TD>
<TD STYLE="width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S&#45;T&nbsp;Rule&nbsp;101(b)(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
<TD STYLE="width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S&#45;T&nbsp;Rule&nbsp;101(b)(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
<TD STYLE="width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 16, 2021, CureVac N.V. (the &#8220;Company&#8221;) issued
a press release with the Company&#8217;s collaboration partner, GlaxoSmithKline Biologicals SA, announcing the publication of preclinical
data of the jointly developed second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 and the Company&#8217;s first-generation
vaccince candidate, CVnCoV, against SARS-CoV-2 in non-human primates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Form 6-K (including Exhibit
99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 16, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.9in; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 0.1in; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><A HREF="tm2125173d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><A HREF="tm2125173d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated August 16, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2125173d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><IMG SRC="tm2125173d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"><B>Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection
in Preclinical Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Preclinical study provides evidence for
strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac&rsquo;s
first-generation mRNA backbone</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Data
demonstrate high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Neutralizing
capacity of induced antibodies tested against a range of variants, including the Beta, Delta and Lambda variant</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>T&Uuml;BINGEN, Germany/ BOSTON, USA/ London, United Kingdom
 &ndash; August 16, 2021</B> &ndash; CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of
transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), and GSK today announced the publication of
preclinical data investigating immune responses as well as the protective efficacy of CureVac&rsquo;s first-generation vaccine
candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates. The study
assessed cynomolgus macaques vaccinated with 12&micro;g of either the first or second-generation vaccine candidate. Better
activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of
antibodies and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. Higher antibody
neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants. During
challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly
effective clearance of the virus in the lungs and nasal passages. The full manuscript of the preclinical data is available on the
preprint server bioRxiv.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;In this animal model, CV2CoV is shown to
induce broad antibody and cellular immune responses very similar to the breadth of the immune responses observed after infection with
SARS-CoV-2,&rdquo; said Dr. Igor Splawski, Chief Scientific Officer of CureVac. &ldquo;The current study shows that the immune responses
and resulting protection produced by our second-generation candidate, based on our mRNA technology featuring targeted optimizations, are
substantially improved in non-human primates against both the original SARS-CoV-2 virus as well as the Beta and Delta Variants of Concern
and the Lambda Variant of Interest.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Rino Rappuoli, Chief Scientist and head of
GSK Vaccines R&amp;D said: &ldquo;The mRNA technology is a key strategic priority for us, and we are investing significantly in a number
of mRNA programs focused on the collaboration with CureVac. The strong immune response and protection in pre-clinical testing of this
second-generation mRNA backbone are very encouraging and represent an important milestone for its further development.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within the study, CVnCoV and CV2CoV were
tested in cynomolgus macaques immunized with a 12&micro;g dose of the respective candidate on day 0 and day 28. Induction of innate
immunity was investigated via specific cytokine markers. Adaptive immune responses were assessed based on receptor binding domain
specific antibodies and neutralizing antibodies as well as memory B and T cells. Impact of Variants of Concern and Variants of
Interest on neutralizing antibody titers was tested against the Alpha, Beta, Delta, Kappa and the Lambda variant. Clearance of the
virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CureVac-GSK COVID-19 collaboration announced
in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the
development of new products based on CureVac&rsquo;s second-generation mRNA-technology for different targets in the field of infectious
diseases. The optimized mRNA backbone that is being used in this collaboration also has the potential for a multivalent or combination
approach to address multiple emerging variants in one vaccine. Following the current preclinical development of CV2CoV, a Phase 1 clinical
trial is expected to start in Q4 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About CV2CoV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CV2CoV is CureVac&rsquo;s first candidate based
on the advanced second-generation mRNA backbone currently developed in collaboration with GSK. The vaccine candidate, presently at a preclinical
development stage, is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus,
and formulated within Lipid Nanoparticles (LNPs). CV2CoV was engineered with specifically optimized non-coding regions to exhibit improved
mRNA translation for increased and extended protein expression compared the first-generation mRNA backbone. Preclinical studies in different
animal models demonstrate CV2CoV&rsquo;s ability to induce earlier and stronger immune responses. The first clinical trial of CV2CoV is
expected to start in Q4 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">CureVac is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile
biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA
as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its
proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered
in T&uuml;bingen, Germany, and employs more than 700 people at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information
can be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About GSK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">GSK is a science-led global healthcare
company with a special purpose: to help people do more, feel better, live longer. For further information please visit <U>www.gsk.com/about-us</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Sarah Fakih, Vice President Corporate Communications and Investor
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anna Kamilli, Manager Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1684</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>anna.kamilli@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bettina J&ouml;dicke-Braas, Manager Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: 49 7071 9883-1087</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>bettina.joedicke-braas@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GSK Enquiries</B></FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media enquiries</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Moore</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44 (0) 20 8047 5502</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(London)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristen Neese</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 804 217 8147</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Philadelphia)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kathleen Quinn</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 202 603 5003</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Washington DC)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analyst/Investor <BR>
enquiries:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Dodwell</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44 (0) 20 8047 2406</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(London)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonya Ghobrial</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44 (0) 7392 784784</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Consumer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mick Readey</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44 (0) 7990 339653</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(London)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff McLaughlin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 215 751 7002</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Philadelphia)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frannie DeFranco</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 215 751 4855</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Philadelphia)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains statements that constitute
 &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of
1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of
CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac
Corporate Services GmbH (the &ldquo;company&rdquo;) regarding future events or future results, in contrast with statements that
reflect historical facts. Examples include discussion of the potential efficacy of the company&rsquo;s vaccine and treatment
candidates and the company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some cases, you can
identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or
 &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements are
based on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However, these
forward-looking statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding,
ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory
approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any
products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing
competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s business
and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors.
Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such
statements. Many of these risks are outside of the company&rsquo;s control and could cause its actual results to differ materially
from those it thought would occur. The forward-looking statements included in this press release are made only as of the date
hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as required by
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s reports
and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website
at www.sec.gov.</P>



<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2125173d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2125173d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 . # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN1\7>+#I9-A8D&[(R
M[]?+!_K6=6K&E!SEL;8?#SQ%14Z:U-_4=:T_2ES=W"HQ&0@Y8_A7+7?Q"7=B
MRLLC^],V/T'^-<')-)/(TLKL\C'+,QR2:;FO K9G6F_<]U?B?2T,FH07[SWG
M^!U$OC35YFRLR1#T2,?US35\3:HY^:]D_ X_E7-@G-3(37GU*U:6\W][.SZG
M0BM(+[CJ8?$5^,9NI#]6S6E;>)[H8\Q@P]Q6;>Z5:6OANSU"$RF6<KNWMP,@
MYP,>HK+C>L:TL5AI)<[O9/=O<X?84*T6U'JUMV/0K+7X+@A9!L/K6L"& (.0
M>AKS.&8JP(-=GX>O&GA>)CG9R*]7*LVJ5:JH5]6]G_F>3C<$J2YX;&U15'5=
M6M='M#<73X!X5!]YCZ"N<BN_$7B0;[7;I]BW1S]YA[=S^E>[4KQ@^5:OLOZT
M.6EAI5(\[:4>[_K7Y'5SW=M:KNN)XXE'=V HM;N"]@$UM(LD9) 9>AQ7.#PC
MIUM$]UJ5Q/=%%W.SL<<?3FM[3$LTT^'[ @2V8;D !'!Y[T4YU'*TTE\[L*M.
MC&%X-M][67^9;HJLM_;/>36JO^^A4.ZX/ -9R^*M*<9669AZK Y'\JMU8+=F
M<:-26T6;5%4K'5['48I)+:<,(O\ 6;E*E?KFJ8\4:4W*32NO]Y('(/XXH=6F
MDGS+4%0JMM*+T-FBLF7Q'IL-@U[))(L"N$9C$W!/3(QG\:T;:YAO+:.XMW$D
M4BAD8=P:T6L>9;&3=IN#W70KZOJD&CZ9-?7!^2,<+GECV ^M9-AXCU*]LHKO
M_A'KCR9!E3'.C$CZ'!K%O2WC3Q2MC&3_ &3I[;IF!X=O\\?3-=9I>KV&HR7%
MO9.#]D?RV4# X]/;M^%;."C'57?Y'%&K*K4=I6CLMM6M]^B*W_"2P1\W5AJ-
MJ/62V8C\US5JUUW2KQ@L%_ SG^ MAOR/-/U+5['28XWO9_+\P[44*69C[ <U
MBW>M^&[Y2+JV:;/=[)R?SVTE'FULS251P=G-?/3\CIP01D'(HK!/ATP#S-(U
M"YLF/(C+&2,^VUNGX5"GB*YTN[CL_$$"0>8<1WD7,3GW_NFIY+_#J4ZW+_$5
MO/I]_3YG244 @C(.0:*@W([B=;:VEG?[D2%V^@&:\,>:?5-1>0@R7%Q+D#KE
MF/ KVK68VET/4(T&6>VD4#W*FO#]*OOL.H6MV%W^3*LFWUP<XKR<SU<(O8^E
MR&'[NK.*][3\F_S.KN]+T30&2VU-[J[O64,Z6Y"K&#[GJ:L3>']#.E+J\-]>
MBR+;641!V0YQSZ?_ %ZD\0:+)XBN$UK1I([B&=0KJSA"K 8[^V*CNY8= \'2
MZ/+/%+?W4F]XXVW"(9'4_P# ?UKFE3C&4N:*Y4M'^6M];FL:DYQARS?.VN9=
MN^EM+?U>Y5L-$L4TAM8U.:9;,R%(8X@-\G) )/;H?RJ.[70);-Y+![N"X3!$
M4V"'Y[$?G5K0O$5DNEG1M8@,EF3\DB\[,G//?KSD4_4_"Z161U+2;H7=D!N(
MSEE']<?G6$H*5*]))Z:]T^_IZ&GM)1K-5Y-:Z?RM=%MOWO\ (T-5./ FE'_:
M7^354@TB*VTS[;JDLD.__4PIC>_OSTKH+"2Q3P[HAOU!0LH0M]T/@X)KF?$<
M=]%K,GVYRY;F)A]TIVQ3QE*,8JM)<VD5;HM-W^AR8:<I2=%.VLG?OKLOU*J.
M-WRY [9-==X3RTD[=@H'ZUQ<1YKT/PU:&WTI9&&&F._\.W^?>N'*:+GC(R7V
M;O\ K[QYG)0HM=SF_'UM.+^SO&5GM%380.@;.3^8Q^5=GIUY:WUE'+9NK1;0
M %_A]B.U3RPQSQ-%,BO&PPRL,@US%QX/>VG:YT.^DLY#UC8DH?Q_QS7T[ISI
M5)5(*ZENNOR/+56G7HQI5'RN.SZ?/_,W-94MHMZJ@DF%L ?2J.A:G8)H5BCW
MENK+"H*M( 0<5F_VOXFTSY;_ $I;R,=9(#R?RS_(5K:;%INKV2WATR*,N2"L
MD2Y!!Q353GJ7AH[;--=12I>SI6GK&^\6GTL4;"6.X\3ZQ-"ZR1?9T7>IR,X/
M>J_AP:W_ &'!]D:Q$&7V^:&W?>/7%=3#;06\9CAA2-#_  HH IT44<$8CB14
M0=%48 JHX=W3;[[>;N1+%*SBH]M]=E8Y73Q,S>(OM6TWNPJXB'R8V'&.]0:+
M-<#1K4)XAM8%"8\IHURGL<FNQ6&))'D2-5=_O,!RWUJL^E:?(Y=[&W9CU)C'
M-3]7DK-/OWZN_0OZW%W36]NSV5NI!;Q0ZEI<MG=7D-^'!61H\#@].!TK@VN]
M6\-+=^&(D>4W#8LY1V5CSC_/!S7I-O9VUH&%O!'%NZ[% S1):6\US#<21*TT
M.?+<CE<]<5W4)N$;25SR<705:7-3=GW\GNM/P.-N()/#^B0Z!I*&;5;I2\S1
M_>4?Q-[>@J*1;O29+.^L="NK9+./RY]S(?-B[YP>N><UW(MX5N&G$2"9AM9\
M?,1Z9IY 8$$ @\$&K]MY>ID\)V=K;>5OZU[G)ZU?6TFN^&;\3(+5C*1*QPHR
MJXR>U;_]LZ7_ -!&T_[_ "_XTZ6WTZ*T\B:*V2W7G8X4*/P-8<][X2B;8EO:
M7$G0);6XD)/_  $4:225GH-N5)MN2U[W[6.H!!&0<@US/CN>TC\,7$-QM:67
M @3^(OGJ/I4K:CKVH#9IVEBRB/'GWQP1]$'/YT^P\,0PW8O]0N)-0O\ M+*,
M*G^ZO04HI0?-)CJ2E6BX06_5[?YLL>&8;JW\-6$5YN\]8N0W4#)P/P&*UJ**
MSD[MLZ(1Y(J/8",C!KP/7M/;1M>O+)AA4<E/38>5_0U[Y7&^.M$,PM==M[9;
MB?3W#RPD?ZV(')'X?R)KCQE'VL--T>UDN+6'KN,MI:?/I_E\REJ46@ZOINER
M7M_-I3+!MCMW&WCN=I'Z]ZST\&6EXC?V1KMM=2 $^60 3^1_I3-7;PWXMN!J
M4&N)873(%DAN5P..G?\ EFJEB^C>&KM;Y-4_M*]C5O*BMT*QAB,99CVZ\"N"
MK&#G[\4UWO\ U]UCU:4:L*5J<I*7\KC=7OM=K;SOYCK;2](N+2,/JXLKY<K/
M%<1G:&!/0_\ ZZU;?4-.\/:)>V=O?B_N;H%?W:D(F1C.?Q_E7%/<//-)-(<O
M(Q=CZDG)IZO7G^VY-812>U]?^&.RIA'/2I)M7O;3UWM>USK]2U2QG\(6%A%/
MON82A=-I'8YYQCO4ECK-GJ6E#3-9<HT?^HNL9*^F?\\BN0#U;LX);NXC@A0O
M(YPJCO4/$U'.]KZ)6Z-&4L'3C!IO9MWZI[G0Z1H_VW5A;I,DT"?-)+'G&W\>
MYKT< *H51@ 8 %9VB:3'I%@L(PTK?-*_J?\  5I5[N7X-8>#;7O2W\O(^8QV
M)]O4T>BV_P PHHHKT#B"BBB@ HHHH @NX[B6#;;3B"3/WRF[CZ5F!-5^T&V&
ML6IG"!S&8!N"DXSC/3(IFO2:C%<V<]I;,\%N_F2N)< J001M&2<9!JK!<7\^
MK7%[96$<LDUI$BW#L5B^5Y25Y&[/S#MW]J:E8B4%)WU^\T/LNN?]!.V'_;M_
M]>D^PZV>NL1K_NVH_J:H'6-5O=6TN&W@-C;/\]P;F!F+XR#&I'0Y .3VYJSK
MVE_;+^RG6R6[V"16221@GW"5R,XY; S@T^=D^R7=_>R8Z3J+_P"LUVY_[9Q(
MO]*:?#J2#_2-2U&;ZW!4?^.XK(T^\U*QTXQQ:==)J-S.N()4(MXC@;E0@G"[
M48YZ$G/?%1M>ZNM_K%UHEM/<QW1A2(3 JL$H#"1L-C@ +QT+8]Z.>0>QAU7X
MO_,WH_#&C(P9K))7'\4Q,A_4FM.&WAMUVP0QQ+Z(H _2N>T&/7+6_9+NWD^P
M3IN!GN1++%*.N3TVMUP/ND''!P+.JZAJ:7RVVF01NZ;&<2*2&!;!&0?E&,\\
M\]J3DWNRHTX1^%6-RBN,.L^*'FNIHK*(VWG+"L B8S0C<=SGG#< 8QW.>G71
MCU#6&GAMA;JSQLBSY7J" 6).?EPI..#DJ1QFD6;-K?6]Y8)>Q/BW=2RNXVC;
MZ\]N_P!*BL=8L-2D>.TG\QDZ@HR_7&0,]1T]1ZUSUI)JEU=V&F,C6>GK9[9E
M:+F4&/&%;L0>Q].^:AOOL_@&T.LW<_G6PD*2A4(8*X&YAR<D>6AQQP&QR0*
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
